An early trial with a specific purpose
NADPARK enrolled 30 people with newly diagnosed Parkinson’s disease who had not yet started treatment. Participants received oral NR or placebo for 30 days in a blinded phase I trial. Researchers investigated tolerability, brain NAD and cerebral metabolism. Brain NAD increased significantly but variably, and related metabolites were measured in cerebrospinal fluid. [1]
Among NR recipients whose brain NAD increased, changes in brain metabolism were associated with mild clinical improvement. The authors called for larger trials. That association is an exploratory signal; it does not establish slowed disease progression or a reliable treatment effect for everyone with Parkinson’s. [1]
Why the responder group needs careful reading
A result described among people who showed a biological response is narrower than a result demonstrated across the entire randomized treatment group. Before interpreting such a finding, ask how the subgroup was defined and whether the analysis was planned. Do not quietly replace “participants with this response” with “patients who take NR.”
The interesting next question is whether a future trial can reproduce a clinically meaningful difference using an analysis that preserves the benefits of randomization. A mechanistic observation helps formulate that question. It does not settle it.
Also separate the purpose of the imaging from a diagnosis or monitoring service sold to consumers. A specialized research measurement is not, by itself, a validated way to choose someone’s supplement regimen.
Disease research is not a healthy-brain claim
The participants were selected because they had a specific neurological disease. A study in that setting cannot be used as a direct answer about memory, concentration or normal aging in healthy adults. “Brain health” is too broad a label to preserve the actual research question.
If a wellness product cites NADPARK, compare the ingredient and route first. This was oral NR research, not a study of a commercial NAD+ infusion. Our ingredient comparison explains that distinction. Next, identify whether the advertised outcome was assessed in the paper or merely inferred from the mechanism.
Where the evidence belongs in a care conversation
Treat NADPARK as a reason for continued clinical investigation, not a reason to alter established care on your own. A useful conversation with a specialist starts with the exact paper, current medications and the outcome you want to understand.
The related NR-SAFE study asked a different question about short-term tolerability at a higher research dose. Together, early studies can inform later trial design. Their existence should not be mistaken for an approved indication or a personalized recommendation. A convincing follow-up would need a prespecified clinical question and enough observation to distinguish a durable treatment effect from a short-term signal.